ANCA-associated vasculitis life expectancy

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of autoimmune diseases characterized by inflammation and damage to small blood vessels. Although AAV life expectancy may be shortened for some people, modern treatments have drastically improved the long-term outlook.

AAV inflammation occurs when the immune system, often led by self-reactive antibodies called ANCAs, mistakenly attacks the cells lining blood vessels throughout the body. The specific symptoms and AAV prognosis depend heavily on the organs and tissues that are damaged.

Left untreated, AAV can lead to serious organ damage and early mortality. However, with proper treatment and proactive monitoring, AAV isn’t always fatal, and many people can have a relatively normal life expectancy.

Factors that influence life expectancy

In recent years, the five-year AAV survival rate after diagnosis is about 70% to 80%. While people with AAV, on average, have a lower life expectancy than their peers in the general population, long-term outcomes vary widely among individuals.

Factors affecting AAV prognosis may include:

• diagnostic delays: a later diagnosis and start to treatment gives time for irreversible organ damage to accumulate
• disease type: each AAV type has a different clinical profile and associated outcomes
• disease activity: more aggressive disease at diagnosis and over time is typically tied to worse outcomes
• organ involvement: kidney, cardiovascular, and respiratory involvement are associated with poorer outcomes
• comorbidities and complications: coexisting conditions and complications like infections can contribute to poor health and worsen the prognosis
• age: younger patients tend to respond more robustly to treatment and have a better outlook

In terms of organ damage and AAV prognosis, kidney involvement in particular is associated with poor outcomes, because it increases the risk of life-threatening kidney failure.

There are three primary types of AAV: microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA).

With modern treatments, GPA and EGPA life expectancies are similar to those of the general population, although frequent relapses (bouts of new disease activity) in GPA can worsen the outlook. MPA prognosis may be poorer than other disease types, often because of kidney problems, although identifying complications early improves the risk profile.

How treatment affects long-term outcomes

Treatment is a major factor that can affect the long-term outlook for AAV. Previously, survival rates one year after diagnosis were about 20%, but in the modern treatment era, they have increased substantially to about 90%.

AAV treatment relies on immunosuppressant medications to control the abnormal immune activity that causes damage. It usually occurs in two phases:

• induction phase: intended to bring on AAV remission, a state of  absent or negligible inflammatory disease activity
• maintenance phase: aims to sustain remission and reduce the risk of AAV relapse

Even with treatment, the relapse risk in AAV is about 30% to 50% over the course of the disease. Patterns of AAV remission and relapse influence patient outcomes. In general, reaching and staying in remission correlates with better outcomes, while relapses correlate with a poorer prognosis.

AAV treatment outcomes may also depend on medication side effects, which can cause complications for some patients.

Regular follow-up care and monitoring are critical for promptly identifying relapses and making necessary treatment adjustments.

Complications that can affect prognosis

Various complications can negatively affect survival with AAV. These may be related to the underlying disease, immunosuppressive treatments, or a combination of both.

Complications likely related to disease activity may include:

• kidney problems: reduced kidney function increases the risk of kidney failure
• lung problems: scarring or bleeding in the lungs can cause respiratory failure
• cardiovascular disease: blood vessel damage, blood clots, and high blood pressure can increase the risk of events like heart attack and stroke

Immunosuppressive treatment hampers the immune system’s ability to fight off threats to the body. This can lead to treatment-related complications such as:

• infections
• certain cancers

Treatments can also cause other complications, such as bone problems or infertility, that are not life-threatening but can impair quality of life.

AAV mortality is highest in the first year after diagnosis, with infections related to aggressive immunosuppressive treatment being a leading cause of death. In the long term, cardiovascular disease and cancer are also leading causes of death.

Proactive monitoring, early intervention, and preventive measures against infections may help reduce these risks.

Living with AAV over time

People living with AAV need to balance treatment and monitoring, relapse management, and medication side effects along with their usual daily life. Strong emotional and practical support systems may help patients maintain this balance and improve quality of life with AAV.

Maintenance therapy for relapse prevention often continues for several years or indefinitely, depending on individual risk. Patients should work with their care team to find a treatment plan that works for them. If a relapse does occur, changes in the treatment regimen may be needed.

Regular follow-up care is vital for managing AAV long term, as it can help prevent complications and reduce other risk factors, improving a person’s overall outlook.